Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJSFTX)

• Drug Name: CPI-006 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMJSFTX

Molecule-Related Drug Atlas

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TJ004309	DMFB54Y	Ovarian cancer	2C73	Phase 2	[4]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
AB680	DMGONUE	Pancreatic cancer	2C10	Phase 1	[6]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[10]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[10]
PMID28870136-Compound-53	DMLEWY6	N. A.	N. A.	Patented	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Not Available	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT03454451) CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
• [4] ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of Agenus.
• [6] Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
• [7] ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
• [8] CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
• [9] Clinical pipeline report, company report or official report of Surface oncology.
• [10] Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.